Background Long-term use of clozapine for individuals with schizophrenia carries a high risk
for developing metabolic abnormalities, especially clozapine-induced weight gain. Previous …

Background Schizophrenia (SC) is considered the most serious of all mental disorders.
Some antipsychotics are associated with weight gain and metabolic abnormalities. Whether …

OBJECTIVE: The second-generation antipsychotic agents clozapine and olanzapine have
been associated with weight gain and increased lipid and glucose blood levels. Since some …

Objective Numerous studies have demonstrated that fluvoxamine has considerable
pharmacokinetic and pharmacodynamic interactions with clozapine. We conducted a 12 …

Objective: The aim of this study was to test whether the initial antipsychotic response to
clozapine is related to subsequent weight change. Method: This study was an 8-year …

Method: This study is a retrospective cohort study combining a cross-sectional survey of
metabolic syndrome and retrospective chart review. The subjects were hospitalized …

Objective To review recent advances in the epidemiology, pathobiology, and management
of weight gain and obesity in patients with schizophrenia and to evaluate the extent to which …

Background: Some, but not all, previous studies have indicated that weight gain is
associated with greater improvement in psychopathology during clozapine treatment …

This study examined patients with schizophrenia in two state hospitals treated with
clozapine, with particular attention to factors that may affect weight gain. A retrospective …